Skip to main content

Table 1 Survival and Tumor Growth Analysis

From: Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model

 

0.4% Direct Topical Rapamycin

0.8% Indirect Topical Rapamycin

0.8% Direct Topical Rapamycin

0.16 mg Injected (IP) Rapamycin

Direct Topical Vehicle

Median Survival (days)

41

54

46

74.5

29.5

   Logrank Analysis*

p = 0.0003

p =< 0.0001

p =< 0.0001

p =< 0.0001

N/A

   Logrank Analysis**

p = 0.62

p = 0.0003

N/A

p =< 0.0001

N/A

Ave. Tumor Vol. (mm 3 )

     

   Day 29

1568 ± 155

1136 ± 101

1212 ± 118

440 ± 65

2736 ± 321

   T test*

p = 0.0014

p =< 0.0001

p =< 0.0001

p =< 0.0001

N/A

   T test**

p = 0.08

p = 0.63

N/A

p = 0.0001

N/A

   Day 45

N/A

2235 ± 246

2869 ± 188

944 ± 166

N/A

   T test**

N/A

p = 0.06

N/A

p =< 0.0001

N/A

Number of Mice

15

12

13

8

12

  1. *Compared to vehicle.
  2. **Compared to 0.8% direct topical rapamycin
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us